DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis, Postmenopausal

Intervention: MK0217, /Duration of Treatment : 12 Months (Drug); Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.

Summary

The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.

Clinical Details

Official title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women With Osteoporosis

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Bone Mineral Density (BMD) in PA lumbar spine at 12 months

Secondary outcome: Bone Mineral Density (BMD) in hip at 12 months; bone turnover at 6 and 12 months

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Patient is postmenopausal (or surgically menopausal) for at least 6 months

- Patient must be diagnosed with osteoporosis

- Patient has spinal anatomy suitable for DEXA of the lumbar spine

Exclusion Criteria:

- Patient is receiving or has received treatment prior to randomization which might

influence bone turnover

- Patient has a history of or evidence for metabolic bone disease (other than

postmenopausal bone loss)

- Patient is receiving or is expected to receive during the course of the study any

medication (other than study medication) which might alter bone or calcium metabolism

Locations and Contacts

Additional Information

Related publications:

Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause. 2004 Jul-Aug;11(4):405-15.

Starting date: April 2001
Last updated: November 19, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017